ALXO Valuation

ALX Oncology Holdings Inc

Add to Watchlist

Advanced Chart

1.020

-0.01(-0.971%)1D

Overview
Forecast
Valuation
Earnings

ALXO Relative Valuation

ALXO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALXO is overvalued; if below, it's undervalued.

Historical Valuation

ALX Oncology Holdings Inc (ALXO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -9.92. The fair price of ALX Oncology Holdings Inc (ALXO) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：1.02

Fair

-0.78

Trailing

Forward

0.12

EV/EBITDA

ALX Oncology Holdings Inc. (ALXO) has a current EV/EBITDA of 0.12. The 5-year average EV/EBITDA is -7.45. The thresholds are as follows: Strongly Undervalued below -31.80, Undervalued between -31.80 and -19.63, Fairly Valued between 4.72 and -19.63, Overvalued between 4.72 and 16.90, and Strongly Overvalued above 16.90. The current Forward EV/EBITDA of 0.12 falls within the Historic Trend Line -Fairly Valued range.

0.11

EV/EBIT

ALX Oncology Holdings Inc. (ALXO) has a current EV/EBIT of 0.11. The 5-year average EV/EBIT is -7.44. The thresholds are as follows: Strongly Undervalued below -31.71, Undervalued between -31.71 and -19.58, Fairly Valued between 4.69 and -19.58, Overvalued between 4.69 and 16.83, and Strongly Overvalued above 16.83. The current Forward EV/EBIT of 0.11 falls within the Historic Trend Line -Fairly Valued range.

0.00

ALX Oncology Holdings Inc. (ALXO) has a current PS of 0.00. The 5-year average PS is -2242.84. The thresholds are as follows: Strongly Undervalued below -33251.15, Undervalued between -33251.15 and -17747.00, Fairly Valued between 13261.31 and -17747.00, Overvalued between 13261.31 and 28765.47, and Strongly Overvalued above 28765.47. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

ALX Oncology Holdings Inc. (ALXO) has a current P/OCF of 0.00. The 5-year average P/OCF is -12.34. The thresholds are as follows: Strongly Undervalued below -48.63, Undervalued between -48.63 and -30.49, Fairly Valued between 5.80 and -30.49, Overvalued between 5.80 and 23.94, and Strongly Overvalued above 23.94. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.78

P/FCF

ALX Oncology Holdings Inc. (ALXO) has a current P/FCF of -0.78. The 5-year average P/FCF is -10.82. The thresholds are as follows: Strongly Undervalued below -45.95, Undervalued between -45.95 and -28.39, Fairly Valued between 6.74 and -28.39, Overvalued between 6.74 and 24.30, and Strongly Overvalued above 24.30. The current Forward P/FCF of -0.78 falls within the Historic Trend Line -Fairly Valued range.

ALX Oncology Holdings Inc (ALXO) has a current Price-to-Book (P/B) ratio of 0.86. Compared to its 3-year average P/B ratio of 1.51 , the current P/B ratio is approximately -43.40% higher. Relative to its 5-year average P/B ratio of 2.77, the current P/B ratio is about -69.06% higher. ALX Oncology Holdings Inc (ALXO) has a Forward Free Cash Flow (FCF) yield of approximately -168.87%. Compared to its 3-year average FCF yield of -109.80%, the current FCF yield is approximately 53.80% lower. Relative to its 5-year average FCF yield of -68.30% , the current FCF yield is about 147.24% lower.

0.85

P/B

Median3y

1.51

Median5y

2.77

-191.83

FCF Yield

Median3y

-109.80

Median5y

-68.30

Competitors Valuation Multiple

The average P/S ratio for ALXO's competitors is 22.49, providing a benchmark for relative valuation. ALX Oncology Holdings Inc Corp (ALXO) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ALXO.O

ALX Oncology Holdings Inc

Incannex Healthcare Inc

74.19

18.37M

COEP.O

Coeptis Therapeutics Holdings Inc

Loss

61.84M

INKT.O

Mink Therapeutics Inc

BioXcel Therapeutics Inc

53.45

-89.13%

52.70M

Performance Decomposition

Market capitalization of ALXO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ALXO in the past 1 year is driven by Unknown.